Home
Search:
1146 feeds
357 categories
0 articles (<24 hours)
30 registered users

Use the Mobile version
Mobile

Follow our Twitter feed

View our Linkpartners
Links

Username:
Password:

Register | Retrieve

General


RSS FeedsOral semaglutide demonstrated cardiovascular safety in people with type 2 diabetes and established cardiovascular disease ...
(WorldNews Denmark)

 
 

12 june 2019 00:00:28

 
Oral semaglutide demonstrated cardiovascular safety in people with type 2 diabetes and established cardiovascular disease ...
(WorldNews Denmark)
 


San Francisco, US, 11 June 2019 - Novo Nordisk today announced that the PIONEER 6 trial achieved its primary endpoint by demonstrating non-inferiority of major adverse cardiovascular events (MACE) with oral semaglutide compared with placebo, both in addition to standard of care. The primary endpoint was defined as the MACE composite outcome of the first occurrence of cardiovascular death, non-fatal myocardial infarction or non-fatal stroke and non-inferiority for cardiovascular safety of oral semaglutide versus placebo was...


 
18 viewsCategory: General > Europe > Denmark
 
Oral semaglutide demonstrated cardiovascular safety in people with type 2 diabetes and established cardiovascular disease or high cardiovascular risk in PIONEER 6 trial
(WorldNews Denmark)
Number of people receiving Danish unemployment benefit hits ten-year low
(WorldNews Denmark)
 
 
blog comments powered by Disqus


Copyright © 2008 - 2024 Indigonet Services B.V.. Contact: Tim Hulsen. Read here our privacy notice.
Other websites of Indigonet Services B.V.: Nieuws Vacatures Science Tweets Nachrichten